The rare bacteria has been linked to dozens of infections, eight cases of vision loss, four eye removals and three patient deaths, according to the CDC.
The CDC has identified 68 patients in 16 states with rare, drug-resistant pseudomonas aeruginosa strains never before reported in the U.S. The majority of patients reported using EzriCare’s artificial tears.
Other adverse reactions include infections of the cornea, bloodstream, respiratory tract and urinary tract.
The CDC began its investigation into pseudomonas infections on Jan. 20.
Upon learning about the issue, EzriCare “immediately took action to stop any further distribution or sale of EzriCare Artificial Tears. To the greatest extent possible, we have been contacting customers to advise them against continued use of the product,” a spokesperson told KSL.
Physicians urge patients to use caution with eyedrops and beware of yellow, green or clear discharge from the eye; eye pain or discomfort; redness of the eye or eyelid; feeling like something is in the eye; increased light sensitivity; and blurry vision.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.